CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer

Open access

Abstract

Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an estimated 50% of patients will eventually stop responding to treatment due to acquired resistance. This study revealed that diminished MEIS1 expression was detected in CRC and harmed the survival of CRC patients. MEIS1 impaired CRC cell viabilities and tumor growth in mice and enhanced CRC cell sensitivity to oxaliplatin by preventing DNA damage repair. Mechanistically, oxaliplatin resistance following MEIS1 suppression was critically dependent on enhanced FEN1 expression. Subsequently, we confirmed that EZH2-DNMT3a was assisted by lncRNA ELFN1-AS1 in locating the promoter of MEIS1 to suppress MEIS1 transcription epigenetically. Based on the above, therapeutics targeting the role of MEIS1 in oxaliplatin resistance were developed and our results suggested that the combination of oxaliplatin with either ELFN1-AS1 ASO or EZH2 inhibitor GSK126 could largely suppress tumor growth and reverse oxaliplatin resistance. This study highlights the potential of therapeutics targeting ELFN1-AS1 and EZH2 in cell survival and oxaliplatin resistance, based on their controlling of MEIS1 expression, which deserve further verification as a prospective therapeutic strategy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-00902-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Diminished MEIS1 expression is detected in CRC and harms the survival of CRC patients. a The TALE subfamily score in paired samples grouped by cancer from TCGA. b Expression levels of MEIS family genes in paired samples grouped by cancer from TCGA. c Expression levels of MEIS family genes in the GEO and TCGA datasets. d qPCR (top) and western blot (bottom) of MEIS1 expression in the normal colon cell line 8401 and CRC cell lines. e qPCR analysis of MEIS1 expression in 12 normal colorectal and 44 CRC samples. f Western blot analysis of MEIS1 expression in 9 pairs of CRC samples and corresponding adjacent normal colorectal samples. g, h IHC of MEIS1 expression in CRC and adjacent nontumor samples. The data are presented as a representative image (g) (top, ×20 magnification; bottom, ×40 magnification) and summary graphs (h) (normal group, n = 23 and cancer group, n = 106). Scale bar, 100 mm. i Kaplan–Meier analysis showing overall survival (OS) curves of CRC patients stratified based on high versus low MEIS1 expression. j ROC curves displaying the sensitivity and specificity of MEIS1 for the diagnosis of CRC patients from the TCGA CRC dataset. Data are presented as the means ± SEM from three independent experiments. **p < 0.05, ****p < 0.0001
Fig. 1 Diminished MEIS1 expression is detected in CRC and harms the survival of CRC patients. a The TALE subfamily score in paired samples grouped by cancer from TCGA. b Expression levels of MEIS family genes in paired samples grouped by cancer from TCGA. c Expression levels of MEIS family genes in the GEO and TCGA datasets. d qPCR (top) and western blot (bottom) of MEIS1 expression in the normal colon cell line 8401 and CRC cell lines. e qPCR analysis of MEIS1 expression in 12 normal colorectal and 44 CRC samples. f Western blot analysis of MEIS1 expression in 9 pairs of CRC samples and corresponding adjacent normal colorectal samples. g, h IHC of MEIS1 expression in CRC and adjacent nontumor samples. The data are presented as a representative image (g) (top, ×20 magnification; bottom, ×40 magnification) and summary graphs (h) (normal group, n = 23 and cancer group, n = 106). Scale bar, 100 mm. i Kaplan–Meier analysis showing overall survival (OS) curves of CRC patients stratified based on high versus low MEIS1 expression. j ROC curves displaying the sensitivity and specificity of MEIS1 for the diagnosis of CRC patients from the TCGA CRC dataset. Data are presented as the means ± SEM from three independent experiments. **p < 0.05, ****p < 0.0001CC BY · PubMed Central
Fig. 2 MEIS1 impairs the viability and DNA replication of CRC cells and tumor growth in mice. a Knockdown of MEIS1 in Caco2 and SW480 cells was confirmed by western blot. b Overexpression of MEIS1 in HCT116 and HCT8 cells was confirmed by western blot. c–h The proliferative ability of cells with MEIS1 knockdown or overexpression was determined by the CCK-8 assay (c, d), colony formation assay (e, f), and EdU assay (g, h). Scale bar: 50 μm. i–l Transplanted xenografts derived from cells with sh-MEIS1 and sh-NC (i, j) or oe-MEIS1 and oe-NC (k, l) were established in BALB/c nude mice (n = 8). Tumor volume and weight were measured (top-left, removed xenografts; bottom-left, tumor size; top-right, weight). The data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2 MEIS1 impairs the viability and DNA replication of CRC cells and tumor growth in mice. a Knockdown of MEIS1 in Caco2 and SW480 cells was confirmed by western blot. b Overexpression of MEIS1 in HCT116 and HCT8 cells was confirmed by western blot. c–h The proliferative ability of cells with MEIS1 knockdown or overexpression was determined by the CCK-8 assay (c, d), colony formation assay (e, f), and EdU assay (g, h). Scale bar: 50 μm. i–l Transplanted xenografts derived from cells with sh-MEIS1 and sh-NC (i, j) or oe-MEIS1 and oe-NC (k, l) were established in BALB/c nude mice (n = 8). Tumor volume and weight were measured (top-left, removed xenografts; bottom-left, tumor size; top-right, weight). The data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 3 MEIS1 enhances oxaliplatin sensitivity to regress CRC cells by preventing DNA repair to trigger apoptosis. a, b si-MEIS1, oe-MEIS1, and corresponding control cells were treated with increasing concentrations of oxaliplatin for 48 h. Cell viability was determined by the CCK-8 assay (left), and the IC50 values were calculated based on nonlinear regression analysis (right). c–f Flow cytometry assays (c, d) and western blotting (e, f) were used to examine the effect of MEIS1 on the apoptosis of cells treated with oxaliplatin (5 μM) for 48 h. g, h Western blot was used to examine the γ-H2A.X levels in CRC cells treated with oxaliplatin (5 μM) for 24 h. i, j IF was used to examine γ-H2A.X foci in CRC cells treated with oxaliplatin (5 μM) for 24 h. k MEIS1 mRNA levels in samples from the GSE69657 dataset. Response, response to oxaliplatin; noResponse, no response to oxaliplatin. l ROC curves for predicting oxaliplatin resistance in the GSE69657 dataset. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 3 MEIS1 enhances oxaliplatin sensitivity to regress CRC cells by preventing DNA repair to trigger apoptosis. a, b si-MEIS1, oe-MEIS1, and corresponding control cells were treated with increasing concentrations of oxaliplatin for 48 h. Cell viability was determined by the CCK-8 assay (left), and the IC50 values were calculated based on nonlinear regression analysis (right). c–f Flow cytometry assays (c, d) and western blotting (e, f) were used to examine the effect of MEIS1 on the apoptosis of cells treated with oxaliplatin (5 μM) for 48 h. g, h Western blot was used to examine the γ-H2A.X levels in CRC cells treated with oxaliplatin (5 μM) for 24 h. i, j IF was used to examine γ-H2A.X foci in CRC cells treated with oxaliplatin (5 μM) for 24 h. k MEIS1 mRNA levels in samples from the GSE69657 dataset. Response, response to oxaliplatin; noResponse, no response to oxaliplatin. l ROC curves for predicting oxaliplatin resistance in the GSE69657 dataset. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 4 Oxaliplatin resistance following MEIS1 suppression is critically dependent on enhanced FEN1 expression. a GSEA plots showing that MEIS1 mRNA expression negatively correlated with DNA damage repair signatures in the TCGA datasets. b GSVA enrichment analysis showing the DNA repair and apoptosis pathways in the high- or low-MEIS1 groups. c Significant correlations were observed between MEIS1 expression and DNA damage repair pathway genes in the GSE9348, TCGA, GSE21510, and GSE32323 datasets. These genes were detected with | R | > 0.3 as the cutoff criterion in the four-cohort profile. Red represents positive correlations and blue represents negative correlations, Genes that were exclusively positive or negative correlations in all four datasets were screened as candidate genes. d qPCR results of the indicated RNA levels in cells transfected with oe-NC or oe MEIS1. e Luciferase reporter assay of the effect of FEN1, SNAPC4, and ZWINT on the transcriptional activity of the MEIS1 promoter. f Schematic showing putative MEIS1-binding sites on the promoter region of FEN1 and design of the indicated primers (top). ChIP-qPCR analysis of the enrichment of MEIS1 on the FEN1 promoter relative to that in control IgG-treated Caco2 and SW480 cells (bottom). g, h Representative western blot image of the FEN1 protein levels in cells with MEIS1 knockdown (g) or overexpression (h). i, j IHC of MEIS1 and FEN1 expression in CRC. Data are presented as a representative image (i) (top, ×20 magnification; bottom, ×40 magnification) and summary graphs(j). Scale bar, 100 µm. k Western blot analyses of MEIS1 and FEN1 expression in Caco2 and SW480 cells. l–n The proliferation of Caco-2 and SW480 cells was evaluated by the CCK-8 (l), cell colony formation (m), and EdU assays (n). o The cell viability and the IC50 values of SW480 cells was evaluated by the CCK-8 following increasing concentrations of oxaliplatin treatment for 48 h. The data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 4 Oxaliplatin resistance following MEIS1 suppression is critically dependent on enhanced FEN1 expression. a GSEA plots showing that MEIS1 mRNA expression negatively correlated with DNA damage repair signatures in the TCGA datasets. b GSVA enrichment analysis showing the DNA repair and apoptosis pathways in the high- or low-MEIS1 groups. c Significant correlations were observed between MEIS1 expression and DNA damage repair pathway genes in the GSE9348, TCGA, GSE21510, and GSE32323 datasets. These genes were detected with | R | > 0.3 as the cutoff criterion in the four-cohort profile. Red represents positive correlations and blue represents negative correlations, Genes that were exclusively positive or negative correlations in all four datasets were screened as candidate genes. d qPCR results of the indicated RNA levels in cells transfected with oe-NC or oe MEIS1. e Luciferase reporter assay of the effect of FEN1, SNAPC4, and ZWINT on the transcriptional activity of the MEIS1 promoter. f Schematic showing putative MEIS1-binding sites on the promoter region of FEN1 and design of the indicated primers (top). ChIP-qPCR analysis of the enrichment of MEIS1 on the FEN1 promoter relative to that in control IgG-treated Caco2 and SW480 cells (bottom). g, h Representative western blot image of the FEN1 protein levels in cells with MEIS1 knockdown (g) or overexpression (h). i, j IHC of MEIS1 and FEN1 expression in CRC. Data are presented as a representative image (i) (top, ×20 magnification; bottom, ×40 magnification) and summary graphs(j). Scale bar, 100 µm. k Western blot analyses of MEIS1 and FEN1 expression in Caco2 and SW480 cells. l–n The proliferation of Caco-2 and SW480 cells was evaluated by the CCK-8 (l), cell colony formation (m), and EdU assays (n). o The cell viability and the IC50 values of SW480 cells was evaluated by the CCK-8 following increasing concentrations of oxaliplatin treatment for 48 h. The data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 5 Epigenetic silencing maintained by the EZH2/DNMT3a complex contributes to suppressed transcription of MEIS1 in CRC. a BSP analysis of CpG methylation sites on the promoter region of MEIS1 in CRC tumor specimens. The color inside the circle represents the average CpG island methylation status obtained from five independent clones (left). The expression of MEIS1 was analyzed by qPCR (right). b Schematic showing the CpG islands of MEIS1 (left), CpG islands (green) and probes (black line). Heatmap with beta values of DNA methylation obtained from ten MEIS1 probes in normal colorectal tissues and CRC tumors from the TCGA 450K array (middle). Correlation analysis of MEIS1 probes and MEIS1 expression levels by the Pearson correlation coefficient (right). c Western blot analysis of MEIS1 expression in HCT116 cells treated with different combinations of epigenetic drugs. d, e Western blot analyses of EZH2 and MEIS1 expression in CRC cell lines transfected with EZH2 shRNA or oe-EZH2, and their corresponding controls. f qPCR analysis of MEIS1 mRNA levels in Caco2 and SW480 cells transfected with oe-NC, oe-DNMT1, oe-DNMT3a, or oe-DNMT3b. g, h Western blot of DNMT3a and MEIS1 expression in CRC cell lines transfected with DNMT3a shRNA, oe-DNMT3a, and their corresponding controls. i ChIP-qPCR analysis of the enrichment of EZH2 on the MEIS1 promoter relative to that of control IgG in HCT116 and HCT8 cells. j ChIP-qPCR analysis of the DNMT3a genomic occupancy and H3K27 methylation status at the MEIS1 promoter. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 5 Epigenetic silencing maintained by the EZH2/DNMT3a complex contributes to suppressed transcription of MEIS1 in CRC. a BSP analysis of CpG methylation sites on the promoter region of MEIS1 in CRC tumor specimens. The color inside the circle represents the average CpG island methylation status obtained from five independent clones (left). The expression of MEIS1 was analyzed by qPCR (right). b Schematic showing the CpG islands of MEIS1 (left), CpG islands (green) and probes (black line). Heatmap with beta values of DNA methylation obtained from ten MEIS1 probes in normal colorectal tissues and CRC tumors from the TCGA 450K array (middle). Correlation analysis of MEIS1 probes and MEIS1 expression levels by the Pearson correlation coefficient (right). c Western blot analysis of MEIS1 expression in HCT116 cells treated with different combinations of epigenetic drugs. d, e Western blot analyses of EZH2 and MEIS1 expression in CRC cell lines transfected with EZH2 shRNA or oe-EZH2, and their corresponding controls. f qPCR analysis of MEIS1 mRNA levels in Caco2 and SW480 cells transfected with oe-NC, oe-DNMT1, oe-DNMT3a, or oe-DNMT3b. g, h Western blot of DNMT3a and MEIS1 expression in CRC cell lines transfected with DNMT3a shRNA, oe-DNMT3a, and their corresponding controls. i ChIP-qPCR analysis of the enrichment of EZH2 on the MEIS1 promoter relative to that of control IgG in HCT116 and HCT8 cells. j ChIP-qPCR analysis of the DNMT3a genomic occupancy and H3K27 methylation status at the MEIS1 promoter. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 6 EZH2/DNMT3a is assisted by lncRNA ELFN1-AS1 in locating the promoter of MEIS1 to suppress MEIS1 expression. a Venn diagram between EZH2-binding lncRNAs identified by catRAPID and upregulated lncRNAs in the TCGA CRC dataset (p < 0.05 and | logFC | ≥ 1). b qPCR analysis of MEIS1 expression levels in CRC cells transfected with shRNAs targeting lncRNAs. c, d qPCR and western blot analysis of the ELFN1-AS1 mRNA and MEIS1 protein levels, respectively, were determined in cells with overexpression (c) or knockdown of ELFN1-AS1 (d). e After separation of the nuclear and cytosolic fractions, the RNA expression levels were measured by qPCR. GAPDH was used as a cytoplasmic control gene, and U6 was used as the nuclear control gene. Data are presented as percentages of GAPDH, U6, and ELFN1-AS1 levels, and total levels for each were taken as 100%. f RIP experiments for IgG, EZH2, and DNMT3a were performed, followed by qPCR to examine the enrichment of ELFN1-AS1. g, h The interaction of full-length (g) and truncated (h) ELFN1-AS1 with EZH2 and DNMT3a was confirmed by RNA pull-down and immunoblotting. i, j ChIP-qPCR analysis of the enrichment of EZH2, DNMT3a and H3K27 methylation status at the MEIS1 promoter in CRC cells with overexpression (i) or knockdown (j) of ELFN1-AS1. k, l BSP analysis of the DNA methylation status of the MEIS1 locus in CRC cells with overexpression (k) or knockdown (l) of ELFN1-AS1. m Correlation of ELFN1-AS1 expression with the MEIS1 DNA methylation status in CRC and normal tissues from the TCGA 450K array by the Pearson correlation coefficient. n Western blot of EZH2, MEIS1, and FEN1 expression in Caco2 and SW480 cells transfected with EZH2 shRNA, oe-ELFN1-AS1, and their corresponding controls. o Western blot of DNMT3a, MEIS1 and FEN1 expression in Caco2 and SW480 cells transfected with DNMT3a shRNA, oe-ELFN1-AS1, and their corresponding controls. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 6 EZH2/DNMT3a is assisted by lncRNA ELFN1-AS1 in locating the promoter of MEIS1 to suppress MEIS1 expression. a Venn diagram between EZH2-binding lncRNAs identified by catRAPID and upregulated lncRNAs in the TCGA CRC dataset (p < 0.05 and | logFC | ≥ 1). b qPCR analysis of MEIS1 expression levels in CRC cells transfected with shRNAs targeting lncRNAs. c, d qPCR and western blot analysis of the ELFN1-AS1 mRNA and MEIS1 protein levels, respectively, were determined in cells with overexpression (c) or knockdown of ELFN1-AS1 (d). e After separation of the nuclear and cytosolic fractions, the RNA expression levels were measured by qPCR. GAPDH was used as a cytoplasmic control gene, and U6 was used as the nuclear control gene. Data are presented as percentages of GAPDH, U6, and ELFN1-AS1 levels, and total levels for each were taken as 100%. f RIP experiments for IgG, EZH2, and DNMT3a were performed, followed by qPCR to examine the enrichment of ELFN1-AS1. g, h The interaction of full-length (g) and truncated (h) ELFN1-AS1 with EZH2 and DNMT3a was confirmed by RNA pull-down and immunoblotting. i, j ChIP-qPCR analysis of the enrichment of EZH2, DNMT3a and H3K27 methylation status at the MEIS1 promoter in CRC cells with overexpression (i) or knockdown (j) of ELFN1-AS1. k, l BSP analysis of the DNA methylation status of the MEIS1 locus in CRC cells with overexpression (k) or knockdown (l) of ELFN1-AS1. m Correlation of ELFN1-AS1 expression with the MEIS1 DNA methylation status in CRC and normal tissues from the TCGA 450K array by the Pearson correlation coefficient. n Western blot of EZH2, MEIS1, and FEN1 expression in Caco2 and SW480 cells transfected with EZH2 shRNA, oe-ELFN1-AS1, and their corresponding controls. o Western blot of DNMT3a, MEIS1 and FEN1 expression in Caco2 and SW480 cells transfected with DNMT3a shRNA, oe-ELFN1-AS1, and their corresponding controls. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001CC BY · PubMed Central
Fig. 7 LncRNA ELFN1-AS1 promotes tumor growth and oxaliplatin resistance by suppressing MEIS1 expression. a qPCR of ELFN1-AS1 mRNA levels in CRC cells and the normal cell line 8401. b qPCR analysis of ELFN1-AS1 expression in 12 normal colorectal samples and 44 CRC samples. c, d CRC cell proliferation was evaluated by the CCK-8 assay. e GSEA plots showing that ELFN1-AS1 mRNA expression was positively correlated with DNA damage repair signatures in the TCGA CRC datasets. f, g The ELFN1-AS1 mRNA and MEIS1 protein levels were determined by qPCR and western blot, respectively. h, i CRC cell proliferation was determined by the CCK-8 assay. j, k The cell viability and the IC50 values of SW480 and HCT8 cells was evaluated by the CCK-8 following increasing concentrations of oxaliplatin treatment for 48 h. l, m Xenograft tumors derived from Caco2 cells with oe-ELFN1-AS1, oe-ELFN1-AS1 + oe MEIS1 and oe-NC (l) or HCT8 cells with sh-ELFN1-AS1, sh-ELFN1-AS1 + sh-MEIS1 and sh-NC (m) in BALB/c nude mice (n = 8). Tumor volume and weight were measured (top-left, removed xenografts; bottom-left, tumor size; top-right, weight). n, o The expression of MEIS1 and FEN1 in xenograft tumors was detected by western blot and qPCR. Data are presented as the mean ± SEM from three independent experiments. ***p < 0.001
Fig. 7 LncRNA ELFN1-AS1 promotes tumor growth and oxaliplatin resistance by suppressing MEIS1 expression. a qPCR of ELFN1-AS1 mRNA levels in CRC cells and the normal cell line 8401. b qPCR analysis of ELFN1-AS1 expression in 12 normal colorectal samples and 44 CRC samples. c, d CRC cell proliferation was evaluated by the CCK-8 assay. e GSEA plots showing that ELFN1-AS1 mRNA expression was positively correlated with DNA damage repair signatures in the TCGA CRC datasets. f, g The ELFN1-AS1 mRNA and MEIS1 protein levels were determined by qPCR and western blot, respectively. h, i CRC cell proliferation was determined by the CCK-8 assay. j, k The cell viability and the IC50 values of SW480 and HCT8 cells was evaluated by the CCK-8 following increasing concentrations of oxaliplatin treatment for 48 h. l, m Xenograft tumors derived from Caco2 cells with oe-ELFN1-AS1, oe-ELFN1-AS1 + oe MEIS1 and oe-NC (l) or HCT8 cells with sh-ELFN1-AS1, sh-ELFN1-AS1 + sh-MEIS1 and sh-NC (m) in BALB/c nude mice (n = 8). Tumor volume and weight were measured (top-left, removed xenografts; bottom-left, tumor size; top-right, weight). n, o The expression of MEIS1 and FEN1 in xenograft tumors was detected by western blot and qPCR. Data are presented as the mean ± SEM from three independent experiments. ***p < 0.001CC BY · PubMed Central
Fig. 8 The EZH2 inhibitor GSK126 or lncRNA ELFN1-AS1 ASO sensitizes HCT116/L-OHP to oxaliplatin. a The IC50 values of oxaliplatin in HCT116/L-OHP cells treated with oxaliplatin (10 μM), GSK126, GSK126 + oxaliplatin (10 μM) and DMSO. b The IC50 values of oxaliplatin in HCT116/L-OHP cells treated with oxaliplatin (10 μM), ASO-ELFN1-AS1, ASO + oxaliplatin (10 μM) and DMSO. c HCT116/L-OHP cells were inoculated into four-week-old male BALB/C nude mice. When the tumors became palpable, they were injected with 0.1% DMSO, oxaliplatin, ASO-ELFN1-AS1, GSK126, ASO-ELFN1-AS1 + oxaliplatin or GSK126 + oxaliplatin. The tumor volume and weight were measured. d IHC of MEIS1, FEN1 and Ki67 in the tumors. e Schematic representation of a model for the major molecular mechanisms (left) and drug intervention hypothesis (right) for the ELFN1-AS1-EZH2-DNMT3a/MEIS1/FEN1 axis in CRC. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, no significance
Fig. 8 The EZH2 inhibitor GSK126 or lncRNA ELFN1-AS1 ASO sensitizes HCT116/L-OHP to oxaliplatin. a The IC50 values of oxaliplatin in HCT116/L-OHP cells treated with oxaliplatin (10 μM), GSK126, GSK126 + oxaliplatin (10 μM) and DMSO. b The IC50 values of oxaliplatin in HCT116/L-OHP cells treated with oxaliplatin (10 μM), ASO-ELFN1-AS1, ASO + oxaliplatin (10 μM) and DMSO. c HCT116/L-OHP cells were inoculated into four-week-old male BALB/C nude mice. When the tumors became palpable, they were injected with 0.1% DMSO, oxaliplatin, ASO-ELFN1-AS1, GSK126, ASO-ELFN1-AS1 + oxaliplatin or GSK126 + oxaliplatin. The tumor volume and weight were measured. d IHC of MEIS1, FEN1 and Ki67 in the tumors. e Schematic representation of a model for the major molecular mechanisms (left) and drug intervention hypothesis (right) for the ELFN1-AS1-EZH2-DNMT3a/MEIS1/FEN1 axis in CRC. Data are presented as the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, no significanceCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 166

Metadata

Authors
Li, Y., Gan, Y., Liu, J., Li, J., Zhou, Z., Tian, R., Sun, R., Liu, J., Xiao, Q., Li, Y., Lu, P., Peng, Y., Peng, Y., Shu, G., & Yin, G.
Affiliations
Central South University (CN)
Corresponding author
Yin, Gang
Venue
Signal Transduction and Targeted Therapy
Published
2022-03-30
Volume
7
Issue
1
Pages
87-87
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4220837638
Cited by
153
References
53
Citations by year
2026: 19 · 2025: 38 · 2024: 50 · 2023: 36 · 2022: 10
FWCI
14.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82173376)
  • Key Project of Hunan Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
MEIS1, EZH2, DNMT3A, oxaliplatin resistance, colorectal cancer, FEN1, DNA repair, long non-coding RNA, transcriptional repression, GSK126, antisense oligonucleotides, tumor growth
MeSH terms
Enhancer of Zeste Homolog 2 Protein, Oxaliplatin, Animals, Cell Transformation, Neoplastic, Humans, Colorectal Neoplasms, Down-Regulation, Cell Proliferation, Mice, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41392-022-00902-6
The paper
Li, Y., Gan, Y., Liu, J., Li, J., Zhou, Z., Tian, R., Sun, R., Liu, J., Xiao, Q., Li, Y., Lu, P., Peng, Y., Peng, Y., Shu, G., & Yin, G. (2022). Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-00902-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.